Upsher-Smith Launches Osteoporosis Therapy Fortical In U.S.
This article was originally published in The Pink Sheet Daily
Executive Summary
Unigene's nasal calcitonin-salmon product is expected to be sold primarily through managed care as an "economical alternative" to competing agents.
You may also be interested in...
Upsher-Smith/Unigene Suit Over Fortical Triggers 30-Month Stay Of Apotex' ANDA
Product approved under 505(b)(2) now faces encroachment through traditional generic pathway.
NDAs Should Include More Cross-Study Analysis, FDA Says In Draft Guidance
FDA is clarifying that it expects sponsors to provide analysis of efficacy data rather than simply a summary of clinical data as part of the integrated summary of effectiveness in new drug applications